PTO

Under the Paperwork Reduction Act of 1995, no persons are required to r	Uno	der th	e Pa	perw	ork	Rec	luctio	on	Act	of	199	5,	no	рe	rsc	ns	аге	rec	uir	ed	to i

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney	Docket No.	1735.0470001/RWE/ALS		
First Inv	ventor	Shailaja Kasibhatla	:	
Title	Method of Id	lentifying Immunosuppressive Agents	-	
Express	Mail Label No.			

		APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.						Assistant Commissioner for Patents Box Patent Application Washington, DC 20231							
	1.		(Submit an original,	I Form (e.g., PTO/SB/17) I, and a duplicate for fee processions small entity status.	ng)	 CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) 									
	3.	×	Specification	[Total Pages 4	14]	 a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or 									
			- Descriptive title of - Cross Reference to	o Related Applications					paper	z copies), oi					
ı			- Reference to seque	ing Fed sponsored R & D ence listing, a table, gram listing appendix		(c. 🔲	Statemen	ts verifying identity	of above copies					
Ì			- Background of the - Brief Summary of	Invention				ACCO	OMPANYING AI	PPLICATION PARTS					
7				of the Drawings (if filed) on		9.		Assignme	ent Papers (cover she	et & document(s))					
but they	4. [2	3		J.S.C. 113) [Total Sheets	5]	10.		37 CFR 3 (when there	.73(b) Statement e is an assignee)	Power of Attorney					
	5. (Oath	or Declaration	[Total Pages _] =	11.		English T	ranslation Documen	t (if applicable)					
There then!	a. Newly executed (original or copy)							Information Statement	on Disclosure t (IDS)/PTO-1449	Copies of IDS Citations					
Taper Three		b		a prior application (37 CF. htion/divisional with Box 18 c		13.		Prelimina	ry Amendment						
			Si	DELETION OF INVENTO	ting inventor(s)	14.			eceipt Postcard (MPF specifically itemized)	EP 503)					
Sant Vanil Isa				med in the prior application, see 37 CFR §§ 53(d)(2) and 1.33(b).		15.		Certified ((if foreign p	Copy of Priority Doc priority is claimed)	cument(s)					
Ji Bance He	6. Application Data Sheet. See 37 CFR 1.76.							16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.							
						17.	\boxtimes	Other:	Authorization under	37 C.F.R. § 1.136(a)(3)					
ı							×	Other:	The name of the assi	gnee is: Cytovia, Inc.					
	18. or in	If	a CONTINUING Application Data Sh	APPLICATION, check applete under 37 CFR 1.76:	propriate box, and sup	ply th	e requ	isite inform	nation below and in a	a preliminary amendment,					
			Continuation infor		ntinuation-in-Part (CI	P)	of p	rior applica <i>Group/Ai</i>	tion No:/ rt Unit:						
ı,	For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can or be relied upon when a portion has been inadvertently omitted from the submitted application parts.														
					19. GARRESPO	NPE	NCE	ADDRES	S						
	×	C	ustomer Number or B	ar Code Label '			*****		or	ondence address below					
ı			Customer No. 26		Custome 26111	chiha	r/coda	label here)							
ŀ	NA	ME		STERNE, KESSLER, GOLDSTEIN		OFFICE	SLVHE	oci:ncie)							
	Attorneys at Law ADDRESS 1100 New York Avenue, N.W. CITY Washington STATE DC ZIP CODE 20005														
ŀ															
ł		UNT	'RY	U.S.	TELEPHONE		2) 371	-2600	FAX	(202) 371-2540					
Ī				Johant W. Esmand			Do	riptration M	O. (Attorney/Agent)	32,893					
ŀ			(Print/Type) R URE	Robert W. Esmond	mon		Tres	sur anon N	o. (Anomey/Agent)	Date August 2, 2001					



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W. . WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 . FACSIMILE: (202) 371-2540 . www.skgf.com



ROBERT GREENE STERNE EDWARD J. KESSLER JORGE A. GOLDSTEIN SAMUEL L. FOX***
DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G. DURKIN MICHELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE MICHAEL O. LEE STEVEN R. LUDWIG

JOHN M. COVERT
LINDA E. ALCORN
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN

LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER
JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
GRANT E. REED

VINCENT L. CAPUANO
JOHN A. HARROUN*
ALBERT J. FASULO II*
ELDORA ELLISON FLOYD*
W. RUSSELL SWINDELL
THOMAS C. FIALA
BRIAN J. DEL BUONO*
VIRGIL L. BEASTON*
RYAN J. STAMPER*
KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
ANDREA J. KAMAGE**
NANCY J. LEITH**

ELIZABETH J. HAANES**
MARK P. TERRY**
JOSEPH M. CONRAD, III**
DOUGLAS M. WILSON**
REGINALD D. LUCAS**
ANN E. SUMMERFIELD**
CYNTHIA M. BOUCHEZ***
HELENE C. CARLSON**
BRUCE E. CHALKER**
DUSTIN T. JOHNSON**
MATTHEW J. DOWD**

August 2, 2001

*LIMITED TO MATTERS
AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
**REGISTERED PATENT AGENT
***SENIOR COUNSEL

WRITER'S DIRECT NUMBER: (202) 371-2560
INTERNET ADDRESS: RESMOND@SKGF.COM

Commissioner for Patents Washington, D.C. 20231

Box Patent Application

Da.

U.S. Non-Provisional Patent Application under 37 C.F.R. § 1.53(b)

Appl. No. To be assigned; Filed: August 2, 2001 (Herewith)
For: Method of Identifying Immunosuppressive Agents

Inventors:

Kasibhatla *et al*.

Our Ref:

1735.0470001/RWE/ALS

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. USPTO Utility Patent Application Transmittal Form (PTO/SB/05)(in duplicate);
- 2. U.S. Utility Patent Application entitled:

Method of Identifying Immunosuppressive Agents

and naming as inventors:

Shailaja Kasibhatla Douglas R. Green Ben Tseng Commissioner for Patents August 2, 2001 Page 2

the application consisting of:

- a. A specification containing:
 - i. 34 pages of description prior to the claims;
 - ii. 9 pages of claims (35 claims);
 - iii. 1 page abstract;
- b. 5 sheets of drawings: (Figures 1-2; 3, 4, 5, and 6);
- c. 1 page of a paper copy of the sequence listing;
- d. A computer readable copy of the sequence listing. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same;
- e. an Application Data Sheet (37 C.F.R. § 1.76);
- 3. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3)(in duplicate); and
- 4. Two (2) return postcards.

The name of the assignee is Cytovia, Inc.

Send correspondence to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond

Attorney for Applicants Registration No. 32,893





In re application of:

Kasibhatla et al.

Appl. No. To be assigned

Filed: August 2, 2001 (Herewith)

For:

Method of Identifying

Immunosuppressive Agents

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 1735.0470001/RWE/ALS

Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents Washington, D.C. 20231

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply. A duplicate copy of this authorization is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond

Attorney for Applicants

Registration No. 32,893

1100 New York Avenue, N.W.

Suite 600

Washington, D.C. 20005-3934

(202) 371-2600